Literature DB >> 6290055

Etoposide single-agent chemotherapy for solid tumors.

W F Jungi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6290055     DOI： 10.1016/s0305-7372(82)80075-3

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  4 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group.

Authors:  F Kung; F A Hayes; J Krischer; D Mahoney; B Leventhal; G Brodeur; D H Berry; R Dubowy; S Toledano
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

3.  Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer.

Authors:  B A Ponder; R T Oliver
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease.

Authors:  H I Scher; C Sternberg; W D Heston; R C Watson; D Niedzwiecki; T Smart; P Hollander; A Yagoda
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.